11.1 Pricing Mechanics
Key Takeaways
WAC (Wholesale Acquisition Cost) is the manufacturer's catalog list price to wholesalers — a starting benchmark before any discounts, rebates, or chargebacks are applied
AWP (Average Wholesale Price) is a published sticker price used as a benchmark for reimbursement and ingredient-cost pricing, though it is criticized as inflated and many payers have shifted toward WAC and other benchmarks
A chargeback is a manufacturer credit to a wholesaler that reconciles the difference between the WAC the wholesaler initially billed and the lower GPO/contract price the pharmacy or hospital actually paid
Rebates are retrospective manufacturer payments to payers, PBMs, or GPOs, usually tied to volume, market share, or formulary placement — distinct from upfront discounts
NADAC (National Average Drug Acquisition Cost) and ASP (Average Sales Price) are additional benchmarks used by Medicaid and Medicare payers to set reimbursement
Scope note: WAC, AWP, NADAC, ASP, cost-plus pricing, and the chargeback/rebate mechanics below are not named anywhere in PTCB's official content outline for this Suppliers and Supply Chain Entities domain. They are covered here as professional financial-mechanics background that explains why chargebacks and GPO contracts (an outline-named Domain 2 contract type) work the way they do — not as confirmed exam topics.
U.S. prescription drug pricing is not a single sticker price. It is a layered system of list prices, benchmarks, discounts, chargebacks, and retrospective rebates that move money between manufacturers, wholesalers, GPOs, pharmacies, and payers. Even though PTCB's outline does not itemize these pricing benchmarks by name, understanding them conceptually — what each benchmark and mechanism means and how they relate, not exact dollar amounts — helps make sense of the GPO and 340B contract types the outline does name.
The List Price: WAC
Wholesale Acquisition Cost (WAC) is the manufacturer's catalog list price to wholesalers. It is a starting price — the price a wholesaler would pay if no discounts, rebates, or contract pricing applied. WAC is best understood as a benchmark, not the final transaction price.
Key points about WAC:
- Published by the manufacturer as a list/catalog price
- Used as a reference point for contracts, chargebacks, and reimbursement formulas
- Does not reflect the net price after discounts, rebates, or chargebacks
- A drug may have a WAC of $100 per unit while the actual net acquisition cost to a pharmacy is far lower after contract pricing
Think of WAC like the MSRP on a car — it is the posted list price, but almost no one pays it after incentives.
The Sticker Benchmark: AWP
Average Wholesale Price (AWP) is a published list or sticker price widely used as a benchmark for reimbursement and ingredient-cost pricing. AWP has historically been used in pharmacy reimbursement formulas (e.g., AWP minus a percentage), but it is criticized as inflated relative to actual acquisition costs.
Because of that criticism, many payers have moved toward other benchmarks — WAC, NADAC, or ASP. Focus on the role of AWP (a reimbursement benchmark) rather than memorizing a specific number. The important distinction is that AWP is a published benchmark, not necessarily what any buyer actually pays.
| Benchmark | What It Is | Role |
|---|---|---|
| WAC | Manufacturer catalog list price to wholesalers | Starting list price; chargeback reference |
| AWP | Published sticker price (widely cited) | Reimbursement/ingredient-cost benchmark; criticized as inflated |
| NADAC | National Average Drug Acquisition Cost | Medicaid benchmark; survey-based actual acquisition cost |
| ASP | Average Sales Price | Medicare Part B benchmark; manufacturer-reported post-discount price |
Cost-Plus Pricing
Cost-plus is a pricing model in which a markup is added to the actual acquisition cost of the product. Unlike AWP- or WAC-based formulas that start from a published list price, cost-plus starts from what the pharmacy or provider actually paid and adds an agreed percentage or fixed markup.
Cost-plus offers transparency — the payer can see the real cost plus an agreed margin. Some Medicaid programs and certain contracts use cost-plus or actual acquisition cost (AAC) models to avoid the inflation problems associated with AWP.
Chargebacks: Reconciling Contract Pricing
A chargeback is the mechanism that makes GPO contract pricing work through the wholesaler channel. Here is the flow:
- A manufacturer and a GPO negotiate a contract price below WAC for member pharmacies/hospitals.
- A member pharmacy orders the product through its wholesaler.
- The wholesaler initially bills the transaction at WAC (its normal catalog price).
- Because the pharmacy is on a GPO contract, it actually pays the lower contract price.
- The wholesaler submits a chargeback to the manufacturer, who credits the wholesaler the difference between WAC and the contract price.
The chargeback reconciles the wholesaler's books so the wholesaler is not out the difference between the WAC it paid/recorded and the contract price the member paid. Without chargebacks, wholesalers could not honor GPO contracts without losing money on every sale. The diagram below shows this reconciliation flow.
Simple Illustrative Example (Conceptual Only)
Suppose a product has a WAC of $100. A GPO contract price is $80. The member pharmacy orders one unit through its wholesaler:
- Wholesaler bills the pharmacy at WAC: $100, but the pharmacy pays the contract price $80.
- The wholesaler is short $20 (the difference between WAC and contract price).
- The wholesaler submits a chargeback to the manufacturer for $20.
- The manufacturer credits the wholesaler $20, reconciling the transaction.
The numbers here are illustrative — the exam does not test exact dollar figures, but it may describe this flow and ask you to identify the chargeback as the manufacturer credit that reconciles WAC to the contract price.
Rebates: Retrospective Manufacturer Payments
A rebate is a manufacturer payment made after the fact (retrospectively) to a payer, PBM, or GPO. Rebates are typically tied to:
- Volume — total units purchased over a period
- Market share — the manufacturer's share of a therapeutic category (often tiered: higher share → higher rebate %)
- Formulary placement — preferred brand status on a payer's formulary in exchange for a rebate
Rebates vs Discounts
The critical distinction is timing and direction:
- A discount is an upfront reduction in the price at the time of sale.
- A rebate is a retrospective payment back to the payer after sales have occurred, often calculated quarterly or annually based on agreed metrics.
Rebates may be structured in tiers: if a manufacturer's product exceeds a target market-share percentage in a therapeutic category, the rebate percentage increases. This rewards the payer for steering volume toward the manufacturer's product.
Who Receives Rebates?
- PBMs negotiate rebates with manufacturers on behalf of the plans they administer (more in Section 11.3).
- GPOs may negotiate rebates for members.
- Payers (insurers, Medicaid programs) may receive rebates directly or through a PBM.
The question of whether rebate savings are passed through to the patient at the pharmacy counter is a known industry issue — but for the exam, focus on the mechanic: rebates are retrospective, volume/market-share/formulary-tied manufacturer payments.
Other Payer Benchmarks: NADAC and ASP
Two additional benchmarks are worth recognizing:
- NADAC (National Average Drug Acquisition Cost) — a survey-based benchmark of what pharmacies actually pay to acquire drugs, used primarily by Medicaid programs to set reimbursement. NADAC is closer to actual acquisition cost than AWP.
- ASP (Average Sales Price) — a manufacturer-reported price that reflects sales after discounts and rebates, used primarily by Medicare Part B for physician-administered drugs. Because ASP nets out discounts, it is generally lower than WAC or AWP.
These benchmarks matter because they determine reimbursement — what a payer pays a pharmacy or provider for a drug. A pharmacy that acquires a product for less than the reimbursement benchmark earns a positive margin; one that acquires above it loses money.
Putting It Together
The pricing stack works like this:
- Manufacturer sets WAC (list price).
- GPO/contract price sits below WAC; chargebacks reconcile the wholesaler.
- Wholesaler sells to the pharmacy at the contract or WAC price.
- Rebates flow retrospectively from manufacturer to PBM/payer/GPO based on volume/market share/formulary.
- Payer reimburses the pharmacy using a benchmark (AWP, WAC, NADAC, ASP, or cost-plus).
This background is here so you can identify each piece and its role and see how the outline-named GPO/340B contract types actually function financially — not because PTCB confirms testing exact net-price computations.
A hospital that is a GPO member orders a drug through its wholesaler. The wholesaler initially bills the transaction at WAC, but the hospital pays the lower GPO contract price. What reconciles the difference between WAC and the contract price?
A retrospective rebate paid by the manufacturer to the hospital
A chargeback submitted by the wholesaler and credited by the manufacturer
An AWP reduction published quarterly by the manufacturer
A cost-plus markup applied by the GPO
Which statement best describes Wholesale Acquisition Cost (WAC)?
The manufacturer's catalog list price to wholesalers, used as a starting benchmark before discounts
The final net price a pharmacy pays after all discounts and rebates
A retrospective payment from the manufacturer to the PBM based on market share
A survey-based average of what pharmacies actually pay to acquire a drug
What is the key difference between a discount and a rebate in drug pricing?
A discount is a retrospective manufacturer payment; a rebate is an upfront price reduction
A discount is an upfront reduction at the time of sale; a rebate is a retrospective payment after sales occur
A discount applies only to brand drugs; a rebate applies only to generics
A discount is paid to the pharmacy; a rebate is paid to the manufacturer
A Medicaid program reimburses a pharmacy using a survey-based benchmark that reflects what pharmacies actually pay to acquire the drug. Which benchmark is this?
AWP (Average Wholesale Price)
ASP (Average Sales Price)
WAC (Wholesale Acquisition Cost)
NADAC (National Average Drug Acquisition Cost)
Sections you finish are checked off in the contents.